Järvinen Tero A H, Rashid Jahidur, Valmari Toini, May Ulrike, Ahsan Fakhrul
Faculty of Medicine and Life Sciences, University of Tampere, Lääkärinkatu 1, 33014 Tampere, Finland.
Department of Orthopedics & Traumatology, Tampere University Hospital, Teiskontie 35, 33520 Tampere, Finland.
ACS Biomater Sci Eng. 2017 Jul 10;3(7):1273-1282. doi: 10.1021/acsbiomaterials.6b00746. Epub 2017 Jan 24.
Growth factors, chemokines, and cytokines responsible for tissue regeneration have been identified. Their therapeutic usage in humans is almost nonexistent because of the difficulty in maintaining their bioactivity in the protease-rich milieu of injured tissues. Safety concerns have ruled out the systemic administration of growth factors. Angiogenic vasculature forming in the regenerating tissues has unique molecular structures, so-called "zip/postal codes". These unique vascular zip codes provide an opportunity for target-specific delivery of systemically administered therapeutics to tissue injuries by ligands (using peptides or antibodies as a delivery vehicle) binding to these specific structures. Molecules with therapeutic potential can also be packaged into nanocarriers which then can be targeted to the desired location by placing large number of peptides on the nanoparticle. The targeted delivery of systemically administered recombinant proteins to the injured tissue is hopefully rapidly advanced to provide new therapeutics to regenerative medicine.
负责组织再生的生长因子、趋化因子和细胞因子已被识别。由于难以在富含蛋白酶的损伤组织环境中维持其生物活性,它们在人类中的治疗用途几乎不存在。安全问题排除了生长因子的全身给药。在再生组织中形成的血管生成血管具有独特的分子结构,即所谓的“邮政编码”。这些独特的血管邮政编码为通过与这些特定结构结合的配体(使用肽或抗体作为递送载体)将全身给药的治疗剂靶向递送至组织损伤提供了机会。具有治疗潜力的分子也可以包装成纳米载体,然后通过在纳米颗粒上放置大量肽将其靶向到所需位置。有望迅速推进将全身给药的重组蛋白靶向递送至损伤组织,为再生医学提供新的治疗方法。